Health is a unity and harmony within the mind, body and spirit which is unique to each person, and is as defined by that person. The level of wellness or health is, in part, determined by the ability to deal with and defend against stress. Health is determined by physiological, psychological, socio-cultural, spiritual, and developmental stage variables.
Tyzeka, Sebivo or telbivudine for patients with chronic hepatitis B - Novartis
Hepatitis :: Tyzeka, Sebivo or telbivudine for patients with chronic hepatitis B - Novartis
Novartis announced the US regulatory approval of Tyzeka(TM) (telbivudine) as a new once-a-day oral treatment for patients with chronic hepatitis B, a disease estimated to affect about 1.25 million people in the US but more than 350 million globally and considered the tenth leading cause of death.Already available in Switzerland, and now approved by the US Food and Drug Administration, telbivudine will be marketed as Sebivo? outside the US. It has also been submitted for regulatory approval with the European Medicines Agency (EMEA) and the Chinese health authority in the first quarter of 2006.
"Profound suppression of the hepatitis B virus is associated with improved outcomes and is a primary treatment goal," said Dr. Adrian M. Di Bisceglie, MD, Professor of Medicine and Chief of Hepatology, Division of Gastroenterology and Hepatology, at St. Louis University, and Co-director, St. Louis University Liver Center, US.
"Tyzeka's ability to provide rapid viral suppression in the first 24 weeks of treatment, along with its demonstrated safety and tolerability profile, make it a promising treatment option for patients," Dr. Di Bisceglie said.
Approximately 1.25 million people in the US are living with chronic hepatitis B, a virus that infects the liver and is 50 to 100 times more infectious than HIV1. Chronic hepatitis B is estimated to affect approximately 350 million people worldwide1 and is the tenth leading cause of death worldwide, responsible for up to 1.2 million deaths each year[2].
"Novartis is committed to infectious diseases and the development of new therapies in the treatment of hepatitis," said Giacomo di Nepi, Head of Infectious Diseases, Transplantation and Immunology at Novartis Pharma AG. "The approval of Tyzeka demonstrates our dedication to provide additional treatment options to patients with chronic hepatitis B and physicians."
About the GLOBE study
The US approval was based primarily on one-year results from the GLOBE study, the largest worldwide registration trial ever conducted in patients with chronic hepatitis B. The primary efficacy endpoint of the GLOBE study was therapeutic response at one year, a composite endpoint coupling viral suppression (serum HBV DNA suppression below 100,000 copies/mL) with either improved liver disease markers (ALT normalization) or loss of detectable hepatitis B e-antigen (HBeAg).
In HBeAg-positive patients, therapeutic response was 75 vs. 67 percent among patients treated with Tyzeka compared to those treated with lamivudine, while the response after one year was 75 vs. 77 percent, respectively, for HBeAg-negative patients taking either treatment. In the phase III registration trial, the majority of Tyzeka-treated patients achieved undetectable levels of virus in the first 24 weeks of treatment, and in 95 percent of those patients the virus remained undetectable at one year.
Patients receiving Tyzeka showed significantly less viral resistance and less treatment failure compared to patients receiving lamivudine at one year. Tyzeka was associated with significantly fewer and less severe elevations ("flares") of serum ALT levels, a potential cause of liver failure in chronic hepatitis B patients, compared to lamivudine. Grade 3-4 creatine kinase (CK) elevations were more common with Tyzeka than lamivudine (7.5 versus 3.1 percent, respectively).
The 52-week GLOBE study results support a favorable overall safety profile for Tyzeka. The type and rate of occurrence of adverse events were similar between Tyzeka-treated patients and lamivudine-treated patients.
Tyzeka has a Category B pregnancy rating. There are no adequate and well-controlled studies of telbivudine in pregnant women. Because animal reproductive toxicity studies are not always predictive of human response, telbivudine should be used during pregnancy only if potential benefits outweigh the risks.
Idenix/Novartis collaboration
Tyzeka is being developed in collaboration between Idenix and Novartis Pharma AG under a development and commercialization arrangement established in May 2003. Idenix is also developing valtorcitabine, another hepatitis B compound, and valopicitabine, a hepatitis C compound, in collaboration with Novartis. Under this agreement, Novartis and Idenix will co-promote telbivudine, valtorcitabine and valopicitabine in the United States, France, Germany, Italy, Spain and the United Kingdom. Novartis has the exclusive right to commercialize telbivudine, valtorcitabine and valopicitabine in the rest of the world.
Novartis is committed to infectious diseases and is developing a portfolio of complementary mechanisms of action in the treatment of hepatitis B and C, while working to bring innovation for serious hospital infections.
About Novartis
Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, treat disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. In 2005, the Group's businesses achieved net sales of USD 32.2 billion and net income of USD 6.1 billion. Approximately USD 4.8 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 people and operate in over 140 countries around the world.
(Hepatitis :: Tyzeka, Sebivo or telbivudine for patients with chronic hepatitis B - Novartis published at SpiritIndia on Wednesday, October 25, 2006)
Hepatitis
Search more information on Hepatitis, Hepatitis booksRecently posted related articles on Hepatitis :
- Hepatitis B :: Decrease in Liver Transplant in Patients with Hepatitis B
- Hepatitis C :: 24-week course of interferon-alpha therapy prolongs survival in patients hepatitis C virus
- Hepatitis C :: Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
- Hepatitis B :: Researchers find way to fight treacherous hepatitis B
- Hepatitis :: HCV and HBV spreading more slowly among injection drug users in San Francisco
- Hepatitis C :: Possible hepatitis C vaccine
- Hepatitis C :: Who will recover spontaneously from hepatitis C virus infection
- Hepatitis C :: Clearance of hepatitis C viral infection after liver transplantation
- Hepatitis A :: Jamba juice employee diagnosed with hepatitis A at a Jamba store in San Jose, California
- Hepatitis B :: Hepatitis B in Indian National Immunisation Programme
Most related articles:
- Hepatitis :: Tyzeka, Sebivo or telbivudine for patients with chronic hepatitis B - Novartis- Hepatitis :: Positive opinion for hepatitis B drug Sebivo - 23.3
- Hepatitis :: Liver disease - Hepatitis - 15.9
- Hepatitis B :: Hepatitis B in Indian National Immunisation Programme - 14.3
- Hepatitis C :: The hepatitis C link - Diagnose, treat, transplant - 14.2
- Hepatitis C :: Hepatitis C - Education and Prevention Initiative in Australia - 14
- Hepatitis :: Hepatitis A cases in Toronto - 13.7
- Hepatitis B :: Decrease in Liver Transplant in Patients with Hepatitis B - 13.5
- Hepatitis B :: Raising Awareness of Chronic Hepatitis B - 13.3
- Hepatitis :: Liver disease - Hepatitis A to G - 13
Hepatitis - recent related articles/news stories:
- New biomarker predicts response to hepatitis C treatment- Positive results of Albuferon in Chronic Hepatitis C
- More cases of hepatitis D reported from Sabarkantha in Gujrat
- Hepatitis C declines health with liver disease
- New hope for hepatitis C sufferers
»» Dyspepsia :: Zelnorm, tegaserod maleate for relief of multiple symptoms of dyspepsia - Novartis
«« Stress :: Better understanding post traumatic stress disorder PTSD
The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com